|
1
|
Germano IM, Emdad L, Qadeer ZA, Binello E
and Uzzaman M: Embryonic stem cell (ESC)-mediated transgene
delivery induces growth suppression, apoptosis and
radiosensitization, and overcomes temozolomide resistance in
malignant gliomas. Cancer Gene Ther. 17:664–674. 2010. View Article : Google Scholar
|
|
2
|
Ulasov IV, Sonabend AM, Nandi S, Khramtsov
A, Han Y and Lesniak MS: Combination of adenoviral virotherapy and
temozolomide chemotherapy eradicates malignant glioma through
autophagic and apoptotic cell death in vivo. Br J Cancer.
100:1154–1164. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Stupp R, Mason WP, van den Bent MJ, et al:
Radiotherapy plus concomitant and adjuvant temozolomide for
glioblastoma. New Engl J Med. 352:987–996. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Jiang H, White EJ, Conrad C, Gomez-Manzano
C and Fueyo J: Autophagy pathways in glioblastoma. Method Enzymol.
453:273–286. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Pan H, Wang H, Zhu L, Mao L, Qiao L and Su
X: The Role of Nrf2 in migration and invasion of human glioma cell
U251. World Neurosurg. Nov 7–2011.(Epub ahead of print).
|
|
6
|
Zhang DD: The Nrf2-Keap1-ARE signaling
pathway: The regulation and dual function of Nrf2 in cancer.
Antioxid Redox Signal. 13:1623–1626. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Lau A, Villeneuve NF, Sun Z, Wong PK and
Zhang DD: Dual roles of Nrf2 in cancer. Pharmacol Res. 58:262–270.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Akhdar H, Loyer P, Rauch C, Corlu A,
Guillouzo A and Morel F: Involvement of Nrf2 activation in
resistance to 5-fluorouracil in human colon cancer HT-29 cells. Eur
J Cancer. 45:2219–2227. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Zhang J, Stevens MF and Bradshaw TD:
Temozolomide: mechanisms of action, repair and resistance. Curr Mol
Pharmacol. 5:102–114. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Wang XJ, Sun Z, Villeneuve NF, et al: Nrf2
enhances resistance of cancer cells to chemotherapeutic drugs, the
dark side of Nrf2. Carcinogenesis. 29:1235–1243. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Levine B, Mizushima N and Virgin HW:
Autophagy in immunity and inflammation. Nature. 469:323–335. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Klionsky DJ, Abeliovich H, Agostinis P, et
al: Guidelines for the use and interpretation of assays for
monitoring autophagy in higher eukaryotes. Autophagy. 4:151–175.
2008. View Article : Google Scholar
|
|
13
|
Mathew R and White E: Autophagy in
tumorigenesis and energy metabolism: friend by day, foe by night.
Curr Opin Genet Dev. 21:113–119. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Jeon SH, Kim SH, Kim Y, et al: The
tricyclic antidepressant imipramine induces autophagic cell death
in U-87MG glioma cells. Biochem Biophys Res Commun. 413:311–317.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Park EJ, Choi KS and Kwon TK:
β-Lapachone-induced reactive oxygen species (ROS) generation
mediates autophagic cell death in glioma U87 MG cells. Chem Biol
Interact. 189:37–44. 2011.
|
|
16
|
Jiang H, Gomez-Manzano C, Aoki H, et al:
Examination of the therapeutic potential of Delta-24-RGD in brain
tumor stem cells: role of autophagic cell death. J Natl Cancer
Inst. 99:1410–1414. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Kaza N, Kohli L and Roth KA: Autophagy in
brain tumors: a new target for therapeutic intervention. Brain
Pathol. 22:89–98. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Jakubowicz-Gil J, Langner E and Rzeski W:
Kinetic studies of the effects of Temodal and quercetin on
astrocytoma cells. Pharmacol Rep. 63:403–416. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Kanzawa T, Germano IM, Komata T, Ito H,
Kondo Y and Kondo S: Role of autophagy in temozolomide-induced
cytotoxicity for malignant glioma cells. Cell Death Differ.
11:448–457. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Natsumeda M, Aoki H, Miyahara H, et al:
Induction of autophagy in temozolomide treated malignant gliomas.
Neuropathology. 31:486–493. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Katayama M, Kawaguchi T, Berger MS and
Pieper RO: DNA damaging agent-induced autophagy produces a
cytoprotective adenosine triphosphate surge in malignant glioma
cells. Cell Death Differ. 14:548–558. 2007. View Article : Google Scholar
|
|
22
|
Kato T, Natsume A, Toda H, et al:
Efficient delivery of liposome-mediated MGMT-siRNA reinforces the
cytotoxity of temozolomide in GBM-initiating cells. Gene Ther.
17:1363–1371. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Voss V, Senft C, Lang V, et al: The
pan-Bcl-2 inhibitor (−)-gossypol triggers autophagic cell death in
malignant glioma. Mol Cancer Res. 8:1002–1016. 2010.
|
|
24
|
Lefranc F: Glioblastomas are resistant to
apoptosis but less resistant to the autophagic process. Bull Mem
Acad R Med Belg. 162:331–338. 2007.(In French).
|
|
25
|
Stepkowski TM and Kruszewski MK: Molecular
cross-talk between the NRF2/KEAP1 signaling pathway, autophagy, and
apoptosis. Free Radic Biol Med. 50:1186–1195. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Gao S, Yang XJ, Zhang WG, Ji YW and Pan Q:
Mechanism of thalidomide to enhance cytotoxicity of temozolomide in
U251-MG glioma cells in vitro. Chin Med J. 122:1260–1266.
2009.PubMed/NCBI
|
|
27
|
Klingelhoeffer C, Kammerer U, Koospal M,
et al: Natural resistance to ascorbic acid induced oxidative stress
is mainly mediated by catalase activity in human cancer cells and
catalase-silencing sensitizes to oxidative stress. BMC Complement
Altern Med. 12:612012. View Article : Google Scholar
|
|
28
|
Lau AT, Wang Y and Chiu JF: Reactive
oxygen species: current knowledge and applications in cancer
research and therapeutic. J Cell Biochem. 104:657–667. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Bjorkoy G, Lamark T, Brech A, et al:
p62/SQSTM1 forms protein aggregates degraded by autophagy and has a
protective effect on huntingtin-induced cell death. J Cell Biol.
171:603–614. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Mizushima N and Yoshimori T: How to
interpret LC3 immunoblotting. Autophagy. 3:542–545. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Aoki H, Kondo Y, Aldape K, et al:
Monitoring autophagy in glioblastoma with antibody against isoform
B of human microtubule-associated protein 1 light chain 3.
Autophagy. 4:467–475. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Lin CJ, Lee CC, Shih YL, et al:
Resveratrol enhances the therapeutic effect of temozolomide against
malignant glioma in vitro and in vivo by inhibiting autophagy. Free
Radic Biol Med. 52:377–391. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Chen H-Y and White E: Role of autophagy in
cancer prevention. Cancer Prev Res. 4:973–983. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Moreau K, Luo S and Rubinsztein DC:
Cytoprotective roles for autophagy. Curr Opin Cell Biol.
22:206–211. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Rao VA, Klein SR, Bonar SJ, et al: The
antioxidant transcription factor Nrf2 negatively regulates
autophagy and growth arrest induced by the anticancer redox agent
mitoquinone. J Biol Chem. 285:34447–34459. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Pan Q, Yang XJ, Wang HM, et al:
Chemoresistance to temozolomide in human glioma cell line U251 is
associated with increased activity of O6-methylguanine-DNA
methyltransferase and can be overcome by metronomic temozolomide
regimen. Cell Biochem Biophys. 62:185–191. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Cho JM, Manandhar S, Lee HR, Park HM and
Kwak MK: Role of the Nrf2-antioxidant system in cytotoxicity
mediated by anticancer cisplatin: implication to cancer cell
resistance. Cancer Lett. 260:96–108. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Nezis IP and Stenmark H: p62 at the
interface of autophagy, oxidative stress signaling, and cancer.
Antioxid Redox Signal. 17:786–793. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Inami Y, Waguri S, Sakamoto A, et al:
Persistent activation of Nrf2 through p62 in hepatocellular
carcinoma cells. J Cell Biol. 193:275–284. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Jain A, Lamark T, Sjottem E, et al:
p62/SQSTM1 is a target gene for transcription factor NRF2 and
creates a positive feedback loop by inducing antioxidant response
element-driven gene transcription. J Biol Chem. 285:22576–22591.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Komatsu M, Kurokawa H, Waguri S, et al:
The selective autophagy substrate p62 activates the stress
responsive transcription factor Nrf2 through inactivation of Keap1.
Nat Cell Biol. 12:213–223. 2010.PubMed/NCBI
|
